Amneal Pharmaceuticals (AMRX) Competitors $7.83 +0.01 (+0.13%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.82 0.00 (-0.06%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. BBIO, VRNA, BPMC, LEGN, ROIV, RGC, ELAN, RVMD, GRFS, and TGTXShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Amneal Pharmaceuticals (NASDAQ:AMRX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Which has more volatility and risk, AMRX or BBIO? Amneal Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Is AMRX or BBIO more profitable? Amneal Pharmaceuticals has a net margin of -0.46% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-0.46% -188.26% 5.34% BridgeBio Pharma -524.25%N/A -94.43% Which has better earnings and valuation, AMRX or BBIO? Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.79B0.88-$116.89M-$0.04-195.75BridgeBio Pharma$221.90M40.53-$535.76M-$3.53-13.42 Do institutionals and insiders hold more shares of AMRX or BBIO? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer AMRX or BBIO? Amneal Pharmaceuticals currently has a consensus price target of $11.60, suggesting a potential upside of 48.15%. BridgeBio Pharma has a consensus price target of $61.18, suggesting a potential upside of 29.15%. Given Amneal Pharmaceuticals' higher possible upside, research analysts clearly believe Amneal Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AMRX or BBIO? In the previous week, BridgeBio Pharma had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 16 mentions for BridgeBio Pharma and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.89 beat BridgeBio Pharma's score of 0.46 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAmneal Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.45B$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-195.708.9728.6723.80Price / Sales0.88639.67422.3188.12Price / Cash5.63157.7635.4557.96Price / Book-22.374.838.275.55Net Income-$116.89M$31.62M$3.24B$259.03M7 Day Performance-2.85%-5.28%-3.63%-4.56%1 Month Performance-6.45%4.38%4.40%4.49%1 Year Performance12.02%-2.49%25.97%18.05% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals3.5129 of 5 stars$7.83+0.1%$11.60+48.1%+9.1%$2.45B$2.79B-195.708,100BBIOBridgeBio Pharma4.706 of 5 stars$46.23-0.2%$61.50+33.0%+80.9%$8.79B$127.42M-13.10400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1781 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.54B$118.54M-52.5530Positive NewsUpcoming EarningsShort Interest ↑BPMCBlueprint Medicines1.0958 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.5818 of 5 stars$41.51-4.3%$73.33+76.7%-29.5%$7.97B$627.24M-70.352,609Positive NewsROIVRoivant Sciences1.8308 of 5 stars$11.35-1.7%$16.50+45.4%+6.5%$7.85B$29.05M-45.40860Upcoming EarningsRGCRegencell Bioscience0.0453 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.7888 of 5 stars$14.59-2.2%$16.17+10.8%+5.9%$7.41B$4.43B19.729,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.4642 of 5 stars$37.26-1.7%$68.91+84.9%-19.1%$7.06B$11.58M-9.32250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.0861 of 5 stars$10.09-0.1%$10.30+2.1%+41.1%$6.94B$7.81B8.6223,822Dividend AnnouncementTGTXTG Therapeutics4.0717 of 5 stars$35.99-2.5%$43.80+21.7%+85.0%$5.86B$329M149.96290Positive NewsUpcoming Earnings Related Companies and Tools Related Companies BBIO Competitors VRNA Competitors BPMC Competitors LEGN Competitors ROIV Competitors RGC Competitors ELAN Competitors RVMD Competitors GRFS Competitors TGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRX Stock Alerts